C2L-OCT-01 PR

· Ambrilia Biopharma, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for C2L-OCT-01 PR, covering 2008-10-08 to 2010-02-09. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients [Phase 3]